Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genta, Inc.

Latest From Genta, Inc.

Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs

The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.

Vaccines Coronavirus COVID-19

Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

Deals Neurology

Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies

Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.

Financing Innovation

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
UsernamePublicRestriction

Register